{ "version": "https://jsonfeed.org/version/1.1", "title": "All conditions clinical trials: new and updated - Open Source Medicine Foundation", "home_page_url": "https://research.opensourcemed.info/clinical_trials.html", "feed_url": "https://research.opensourcemed.info/feeds/all.json", "description": "ClinicalTrials.gov records for All tracked conditions that were newly registered or updated, as tracked by the Open Source Medicine Foundation research tracker. The 30 most recently updated trials, newest first.", "language": "en", "icon": "https://opensourcemed.info/favicon.png", "favicon": "https://opensourcemed.info/favicon.png", "authors": [ { "name": "Open Source Medicine Foundation", "url": "https://opensourcemed.info" } ], "items": [ { "id": "NCT07546539:2026-10-08", "url": "https://clinicaltrials.gov/study/NCT07546539", "title": "Photobiomodulation in Chronic Fatigue Syndrome", "content_text": "Recruiting · Not applicable · Photobiomodulation — The goal of this clinical trial is to evaluate whether photobiomodulation therapy (low-level laser therapy) can reduce fatigue and improve quality of life in patients with chronic fatigue syndrome (CFS). The study will include adults aged 18-60 years diagnosed with chronic fatigue syndrome. The main…", "summary": "Recruiting · Not applicable · Photobiomodulation — The goal of this clinical trial is to evaluate whether photobiomodulation therapy (low-level laser therapy) can reduce fatigue and improve quality of life in patients with chronic fatigue syndrome (CFS). The study will include adults aged 18-60 year", "tags": [ "All conditions", "Recruiting", "Photobiomodulation" ], "_osmf": { "nct_id": "NCT07546539", "status": "RECRUITING", "phase": "NA", "start_date": "2026-06-15", "last_updated": "2026-10-08", "agents": [ "Photobiomodulation" ] }, "date_published": "2026-10-08T08:00:00+00:00", "date_modified": "2026-10-08T08:00:00+00:00" }, { "id": "NCT07388550:2026-10-08", "url": "https://clinicaltrials.gov/study/NCT07388550", "title": "Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)", "content_text": "Not Yet Recruiting · Phase 1 · Keytruda — Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years. These can include neurological symptoms, such as headaches, loss of taste or smell, dizziness, or trouble walking. Pembro…", "summary": "Not Yet Recruiting · Phase 1 · Keytruda — Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years. These can include neurological symptoms, such as headaches, loss of taste or sm", "tags": [ "All conditions", "Not Yet Recruiting", "Keytruda" ], "_osmf": { "nct_id": "NCT07388550", "status": "NOT_YET_RECRUITING", "phase": "PHASE1", "start_date": "2026-10-13", "last_updated": "2026-10-08", "agents": [ "Keytruda" ] }, "date_published": "2026-10-08T08:00:00+00:00", "date_modified": "2026-10-08T08:00:00+00:00" }, { "id": "NCT07285473:2026-10-08", "url": "https://clinicaltrials.gov/study/NCT07285473", "title": "Low-Dose Naltrexone For ME/CFS: Dose-Finding", "content_text": "Not Yet Recruiting · Phase 2 · Low-Dose Naltrexone (LDN) — This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.", "summary": "Not Yet Recruiting · Phase 2 · Low-Dose Naltrexone (LDN) — This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.", "tags": [ "All conditions", "Not Yet Recruiting", "Low-Dose Naltrexone (LDN)" ], "_osmf": { "nct_id": "NCT07285473", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "start_date": "2026-11-01", "last_updated": "2026-10-08", "agents": [ "Low-Dose Naltrexone (LDN)" ] }, "date_published": "2026-10-08T08:00:00+00:00", "date_modified": "2026-10-08T08:00:00+00:00" }, { "id": "NCT06822179:2026-10-08", "url": "https://clinicaltrials.gov/study/NCT06822179", "title": "Effectiveness of a Personalized In-home Telerehabilitation Program on Self-Care in Patients With Long COVID", "content_text": "Completed · Phase 2 · Personalised Exercise Program — The goal of this clinical trial is to evaluate whether a 12-week tele-rehabilitation programme roduces medium-term improvements in self-management, fatigue and quality of life in patients affected by persistent COVID. The main questions it aims to answer are: * Will a multimodal program (exercise wi…", "summary": "Completed · Phase 2 · Personalised Exercise Program — The goal of this clinical trial is to evaluate whether a 12-week tele-rehabilitation programme roduces medium-term improvements in self-management, fatigue and quality of life in patients affected by persistent COVID. The main questions it aims t", "tags": [ "All conditions", "Completed", "Personalised Exercise Program" ], "_osmf": { "nct_id": "NCT06822179", "status": "COMPLETED", "phase": "PHASE2", "start_date": "2025-03-01", "last_updated": "2026-10-08", "agents": [ "Personalised Exercise Program" ] }, "date_published": "2026-10-08T08:00:00+00:00", "date_modified": "2026-10-08T08:00:00+00:00" }, { "id": "NCT06766825:2026-10-08", "url": "https://clinicaltrials.gov/study/NCT06766825", "title": "Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)", "content_text": "Completed · Phase 2 · Plitidepsin 1.5 Mg/Day — The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disabi…", "summary": "Completed · Phase 2 · Plitidepsin 1.5 Mg/Day — The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 sub", "tags": [ "All conditions", "Completed", "Plitidepsin 1.5 Mg/Day" ], "_osmf": { "nct_id": "NCT06766825", "status": "COMPLETED", "phase": "PHASE2", "start_date": "2025-02-07", "last_updated": "2026-10-08", "agents": [ "Plitidepsin 1.5 Mg/Day" ] }, "date_published": "2026-10-08T08:00:00+00:00", "date_modified": "2026-10-08T08:00:00+00:00" }, { "id": "NCT05874037:2026-10-07", "url": "https://clinicaltrials.gov/study/NCT05874037", "title": "Fluvoxamine for Long COVID-19", "content_text": "Completed · Phase 2 · Fluvoxamine — This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is…", "summary": "Completed · Phase 2 · Fluvoxamine — This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID", "tags": [ "All conditions", "Completed", "Fluvoxamine" ], "_osmf": { "nct_id": "NCT05874037", "status": "COMPLETED", "phase": "PHASE2", "start_date": "2023-05-15", "last_updated": "2026-10-07", "agents": [ "Fluvoxamine" ] }, "date_published": "2026-10-07T08:00:00+00:00", "date_modified": "2026-10-07T08:00:00+00:00" }, { "id": "NCT07661862:2026-10-06", "url": "https://clinicaltrials.gov/study/NCT07661862", "title": "PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID", "content_text": "Recruiting · Not applicable · Perceive-Outreach Disease Management Program — Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called \"Long COVID\" or Post-Acute Sequelae of SARS-CoV-2 (PASC). For some people, Long COVID can affect the heart and lungs, making it harder to exercise or carry out daily ac…", "summary": "Recruiting · Not applicable · Perceive-Outreach Disease Management Program — Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called \"Long COVID\" or Post-Acute Sequelae of SARS-CoV-2 (PASC). For some people, Long COVID can a", "tags": [ "All conditions", "Recruiting", "Perceive-Outreach Disease Management Program" ], "_osmf": { "nct_id": "NCT07661862", "status": "RECRUITING", "phase": "NA", "start_date": "2026-04-01", "last_updated": "2026-10-06", "agents": [ "Perceive-Outreach Disease Management Program" ] }, "date_published": "2026-10-06T08:00:00+00:00", "date_modified": "2026-10-06T08:00:00+00:00" }, { "id": "NCT06928272:2026-10-06", "url": "https://clinicaltrials.gov/study/NCT06928272", "title": "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study", "content_text": "Recruiting · Phase 3 · Pirfenidone, Upadacitinib — The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at…", "summary": "Recruiting · Phase 3 · Pirfenidone, Upadacitinib — The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia. To qualify, participants must have had ", "tags": [ "All conditions", "Recruiting", "Pirfenidone", "Upadacitinib" ], "_osmf": { "nct_id": "NCT06928272", "status": "RECRUITING", "phase": "PHASE3", "start_date": "2025-09-10", "last_updated": "2026-10-06", "agents": [ "Pirfenidone", "Upadacitinib" ] }, "date_published": "2026-10-06T08:00:00+00:00", "date_modified": "2026-10-06T08:00:00+00:00" }, { "id": "NCT06404073:2026-10-06", "url": "https://clinicaltrials.gov/study/NCT06404073", "title": "RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))", "content_text": "Completed · Not applicable · Structured Pacing — This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This…", "summary": "Completed · Not applicable · Structured Pacing — This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment ", "tags": [ "All conditions", "Completed", "Structured Pacing" ], "_osmf": { "nct_id": "NCT06404073", "status": "COMPLETED", "phase": "NA", "start_date": "2024-07-17", "last_updated": "2026-10-06", "agents": [ "Structured Pacing" ] }, "date_published": "2026-10-06T08:00:00+00:00", "date_modified": "2026-10-06T08:00:00+00:00" }, { "id": "NCT07398508:2026-10-05", "url": "https://clinicaltrials.gov/study/NCT07398508", "title": "NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease", "content_text": "Recruiting · Phase 1 · Droxidopa Oral Product — This clinical trial will evaluate the safety, tolerability, dosing, and efficacy of Northera (Droxidopa) in children with Menkes disease aged 7 to 17 years who survived the major neurodegenerative and neurocognitive effects of Menkes disease through early Copper Histidinate treatment. The investigat…", "summary": "Recruiting · Phase 1 · Droxidopa Oral Product — This clinical trial will evaluate the safety, tolerability, dosing, and efficacy of Northera (Droxidopa) in children with Menkes disease aged 7 to 17 years who survived the major neurodegenerative and neurocognitive effects of Menkes disease through ea", "tags": [ "All conditions", "Recruiting", "Droxidopa Oral Product" ], "_osmf": { "nct_id": "NCT07398508", "status": "RECRUITING", "phase": "PHASE1", "start_date": "2026-08-10", "last_updated": "2026-10-05", "agents": [ "Droxidopa Oral Product" ] }, "date_published": "2026-10-05T08:00:00+00:00", "date_modified": "2026-10-05T08:00:00+00:00" }, { "id": "NCT05493605:2026-10-01", "url": "https://clinicaltrials.gov/study/NCT05493605", "title": "Cardiac Involvement in Wilson's Disease", "content_text": "Recruiting · Not applicable · Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope — Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical…", "summary": "Recruiting · Not applicable · Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope — Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pedi", "tags": [ "All conditions", "Recruiting", "Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope" ], "_osmf": { "nct_id": "NCT05493605", "status": "RECRUITING", "phase": "NA", "start_date": "2023-03-02", "last_updated": "2026-10-01", "agents": [ "Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope" ] }, "date_published": "2026-10-01T08:00:00+00:00", "date_modified": "2026-10-01T08:00:00+00:00" }, { "id": "NCT07621588:2026-09-29", "url": "https://clinicaltrials.gov/study/NCT07621588", "title": "Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID", "content_text": "Completed · Not applicable · Diaphragmatic Electrostimulation Using Kots Currents, Diaphragmatic Breathing Exercises — This study will evaluate the effects of diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents in patients with Long COVID. Participants will be randomly assigned to one of two groups. The control group will perform diaphragmatic breathing exercises, whi…", "summary": "Completed · Not applicable · Diaphragmatic Electrostimulation Using Kots Currents, Diaphragmatic Breathing Exercises — This study will evaluate the effects of diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents in patients with Long COVID. Participant", "tags": [ "All conditions", "Completed", "Diaphragmatic Electrostimulation Using Kots Currents", "Diaphragmatic Breathing Exercises" ], "_osmf": { "nct_id": "NCT07621588", "status": "COMPLETED", "phase": "NA", "start_date": "2026-06-14", "last_updated": "2026-09-29", "agents": [ "Diaphragmatic Electrostimulation Using Kots Currents", "Diaphragmatic Breathing Exercises" ] }, "date_published": "2026-09-29T08:00:00+00:00", "date_modified": "2026-09-29T08:00:00+00:00" }, { "id": "NCT07468604:2026-09-29", "url": "https://clinicaltrials.gov/study/NCT07468604", "title": "Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition", "content_text": "Recruiting · Phase 4 · 5 Ml Of 0.25% Bupivacaine With Epinephrine — Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per c…", "summary": "Recruiting · Phase 4 · 5 Ml Of 0.25% Bupivacaine With Epinephrine — Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and o", "tags": [ "All conditions", "Recruiting", "5 Ml Of 0.25% Bupivacaine With Epinephrine" ], "_osmf": { "nct_id": "NCT07468604", "status": "RECRUITING", "phase": "PHASE4", "start_date": "2026-05-19", "last_updated": "2026-09-29", "agents": [ "5 Ml Of 0.25% Bupivacaine With Epinephrine" ] }, "date_published": "2026-09-29T08:00:00+00:00", "date_modified": "2026-09-29T08:00:00+00:00" }, { "id": "NCT07021794:2026-09-29", "url": "https://clinicaltrials.gov/study/NCT07021794", "title": "SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)", "content_text": "Recruiting · Phase 2 · Sipavibart — This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.", "summary": "Recruiting · Phase 2 · Sipavibart — This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.", "tags": [ "All conditions", "Recruiting", "Sipavibart" ], "_osmf": { "nct_id": "NCT07021794", "status": "RECRUITING", "phase": "PHASE2", "start_date": "2025-07-28", "last_updated": "2026-09-29", "agents": [ "Sipavibart" ] }, "date_published": "2026-09-29T08:00:00+00:00", "date_modified": "2026-09-29T08:00:00+00:00" }, { "id": "NCT06928116:2026-09-28", "url": "https://clinicaltrials.gov/study/NCT06928116", "title": "Heat thErapy And mobiLity in COVID-19 Survivors", "content_text": "Recruiting · Not applicable · Heat Therapy, Walking — Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Although exercise intervention is a common strategy to restor…", "summary": "Recruiting · Not applicable · Heat Therapy, Walking — Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Althoug", "tags": [ "All conditions", "Recruiting", "Heat Therapy", "Walking" ], "_osmf": { "nct_id": "NCT06928116", "status": "RECRUITING", "phase": "NA", "start_date": "2025-01-16", "last_updated": "2026-09-28", "agents": [ "Heat Therapy", "Walking" ] }, "date_published": "2026-09-28T08:00:00+00:00", "date_modified": "2026-09-28T08:00:00+00:00" }, { "id": "NCT07842302:2026-09-25", "url": "https://clinicaltrials.gov/study/NCT07842302", "title": "Fighting Fatigue in Multiple Sclerosis: TMS vs. tDCS Efficacy.", "content_text": "Not Yet Recruiting · Not applicable · Tms, Tdcs — Multiple Sclerosis (MS) is a chronic neurological disease impacting 2.8 million individuals globally, with fatigue being its most debilitating symptom, reported by 75% of patients. Despite its prevalence, the pathophysiology of MS-related fatigue remains poorly understood, and current pharmacologica…", "summary": "Not Yet Recruiting · Not applicable · Tms, Tdcs — Multiple Sclerosis (MS) is a chronic neurological disease impacting 2.8 million individuals globally, with fatigue being its most debilitating symptom, reported by 75% of patients. Despite its prevalence, the pathophysiology of MS-related fatigue rem", "tags": [ "All conditions", "Not Yet Recruiting", "Tms", "Tdcs" ], "_osmf": { "nct_id": "NCT07842302", "status": "NOT_YET_RECRUITING", "phase": "NA", "start_date": "2026-09", "last_updated": "2026-09-25", "agents": [ "Tms", "Tdcs" ] }, "date_published": "2026-09-25T08:00:00+00:00", "date_modified": "2026-09-25T08:00:00+00:00" }, { "id": "NCT07005921:2026-09-25", "url": "https://clinicaltrials.gov/study/NCT07005921", "title": "QEEG-NEUROFEEDBACK FOR COGNITIVE REHABILITATION IN LONG COVID-19 SURVIVORS WITH BRAIN FOG", "content_text": "Completed · Not applicable · Qeeg-Neurofeedback — The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms of Coronavirus observed in adults. The persistance…", "summary": "Completed · Not applicable · Qeeg-Neurofeedback — The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms ", "tags": [ "All conditions", "Completed", "Qeeg-Neurofeedback" ], "_osmf": { "nct_id": "NCT07005921", "status": "COMPLETED", "phase": "NA", "start_date": "2025-06-10", "last_updated": "2026-09-25", "agents": [ "Qeeg-Neurofeedback" ] }, "date_published": "2026-09-25T08:00:00+00:00", "date_modified": "2026-09-25T08:00:00+00:00" }, { "id": "NCT06631287:2026-09-25", "url": "https://clinicaltrials.gov/study/NCT06631287", "title": "Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID", "content_text": "Recruiting · Phase 3 · Baricitinib — The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomark…", "summary": "Recruiting · Phase 3 · Baricitinib — The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post", "tags": [ "All conditions", "Recruiting", "Baricitinib" ], "_osmf": { "nct_id": "NCT06631287", "status": "RECRUITING", "phase": "PHASE3", "start_date": "2024-10-21", "last_updated": "2026-09-25", "agents": [ "Baricitinib" ] }, "date_published": "2026-09-25T08:00:00+00:00", "date_modified": "2026-09-25T08:00:00+00:00" }, { "id": "NCT07837804:2026-09-24", "url": "https://clinicaltrials.gov/study/NCT07837804", "title": "RESET-POTS: Multimodal Phenotyping and Stellate Ganglion Block in Postural Orthostatic Tachycardia Syndrome", "content_text": "Not Yet Recruiting · Not applicable · Bilateral Sequential Stellate Ganglion Block — RESET-POTS is a pilot study for adults with postural orthostatic tachycardia syndrome (POTS), a condition that can cause a rapid increase in heart rate, dizziness, weakness, fatigue and other symptoms when standing. The study has two parts. In the first part, patients with POTS and healthy volunteer…", "summary": "Not Yet Recruiting · Not applicable · Bilateral Sequential Stellate Ganglion Block — RESET-POTS is a pilot study for adults with postural orthostatic tachycardia syndrome (POTS), a condition that can cause a rapid increase in heart rate, dizziness, weakness, fatigue and other symptoms when standing.", "tags": [ "All conditions", "Not Yet Recruiting", "Bilateral Sequential Stellate Ganglion Block" ], "_osmf": { "nct_id": "NCT07837804", "status": "NOT_YET_RECRUITING", "phase": "NA", "start_date": "2026-10-01", "last_updated": "2026-09-24", "agents": [ "Bilateral Sequential Stellate Ganglion Block" ] }, "date_published": "2026-09-24T08:00:00+00:00", "date_modified": "2026-09-24T08:00:00+00:00" }, { "id": "NCT07123727:2026-09-24", "url": "https://clinicaltrials.gov/study/NCT07123727", "title": "A Study to Examine Anktiva for the Treatment of COVID-19.", "content_text": "Recruiting · Phase 2 · Anktiva — This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.", "summary": "Recruiting · Phase 2 · Anktiva — This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.", "tags": [ "All conditions", "Recruiting", "Anktiva" ], "_osmf": { "nct_id": "NCT07123727", "status": "RECRUITING", "phase": "PHASE2", "start_date": "2025-09-04", "last_updated": "2026-09-24", "agents": [ "Anktiva" ] }, "date_published": "2026-09-24T08:00:00+00:00", "date_modified": "2026-09-24T08:00:00+00:00" }, { "id": "NCT04137757:2026-09-24", "url": "https://clinicaltrials.gov/study/NCT04137757", "title": "fMRI in Postural Tachycardia Syndrome", "content_text": "Active Not Recruiting · Not applicable · Lower Body Negative Pressure — Postural tachycardia syndrome (POTS) is one of the most common forms of chronic orthostatic intolerance in the United States. This is a disabling disorder characterized by an excessive increase in heart rate upon standing that is accompanied by symptoms such as dizziness and fatigue. One of the most…", "summary": "Active Not Recruiting · Not applicable · Lower Body Negative Pressure — Postural tachycardia syndrome (POTS) is one of the most common forms of chronic orthostatic intolerance in the United States. This is a disabling disorder characterized by an excessive increase in heart rate upon standing that i", "tags": [ "All conditions", "Active Not Recruiting", "Lower Body Negative Pressure" ], "_osmf": { "nct_id": "NCT04137757", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "start_date": "2022-02-18", "last_updated": "2026-09-24", "agents": [ "Lower Body Negative Pressure" ] }, "date_published": "2026-09-24T08:00:00+00:00", "date_modified": "2026-09-24T08:00:00+00:00" }, { "id": "NCT06847191:2026-09-22", "url": "https://clinicaltrials.gov/study/NCT06847191", "title": "NE3107 in Adults With Neurological Symptoms of Long COVID", "content_text": "Completed · Phase 2 · Ne3107 — Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things (\"brain fog\") and fa…", "summary": "Completed · Phase 2 · Ne3107 — Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remember", "tags": [ "All conditions", "Completed", "Ne3107" ], "_osmf": { "nct_id": "NCT06847191", "status": "COMPLETED", "phase": "PHASE2", "start_date": "2025-04-29", "last_updated": "2026-09-22", "agents": [ "Ne3107" ] }, "date_published": "2026-09-22T08:00:00+00:00", "date_modified": "2026-09-22T08:00:00+00:00" }, { "id": "NCT06739720:2026-09-21", "url": "https://clinicaltrials.gov/study/NCT06739720", "title": "RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue", "content_text": "Recruiting · Phase 2 · Lingzhi Capsule — The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it sa…", "summary": "Recruiting · Phase 2 · Lingzhi Capsule — The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi sup", "tags": [ "All conditions", "Recruiting", "Lingzhi Capsule" ], "_osmf": { "nct_id": "NCT06739720", "status": "RECRUITING", "phase": "PHASE2", "start_date": "2025-01-02", "last_updated": "2026-09-21", "agents": [ "Lingzhi Capsule" ] }, "date_published": "2026-09-21T08:00:00+00:00", "date_modified": "2026-09-21T08:00:00+00:00" }, { "id": "NCT06721949:2026-09-18", "url": "https://clinicaltrials.gov/study/NCT06721949", "title": "Taurine Supplementation in Long COVID", "content_text": "Recruiting · Phase 2 · Taurine — The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS…", "summary": "Recruiting · Phase 2 · Taurine — The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating sym", "tags": [ "All conditions", "Recruiting", "Taurine" ], "_osmf": { "nct_id": "NCT06721949", "status": "RECRUITING", "phase": "PHASE2", "start_date": "2025-11-18", "last_updated": "2026-09-18", "agents": [ "Taurine" ] }, "date_published": "2026-09-18T08:00:00+00:00", "date_modified": "2026-09-18T08:00:00+00:00" }, { "id": "NCT06472622:2026-09-18", "url": "https://clinicaltrials.gov/study/NCT06472622", "title": "Functional Neuroimaging to Detect the Neural Signatures of the Unpleasantness of Pain and Effort", "content_text": "Recruiting · Early phase 1 · Thermal Pain Stimulation, Physical Effort Stimulation — Background: The way the brain processes rewards and punishments may play a role in some disorders of the nervous system. People with chronic overlapping pain conditions (such as myalgic encephalomyelitis/chronic fatigue syndrome \\[ME/CFS\\]) may have heightened responses to unpleasant, punishing sens…", "summary": "Recruiting · Early phase 1 · Thermal Pain Stimulation, Physical Effort Stimulation — Background: The way the brain processes rewards and punishments may play a role in some disorders of the nervous system. People with chronic overlapping pain conditions (such as myalgic encephalomyelitis/chronic fat", "tags": [ "All conditions", "Recruiting", "Thermal Pain Stimulation", "Physical Effort Stimulation" ], "_osmf": { "nct_id": "NCT06472622", "status": "RECRUITING", "phase": "EARLY_PHASE1", "start_date": "2025-04-09", "last_updated": "2026-09-18", "agents": [ "Thermal Pain Stimulation", "Physical Effort Stimulation" ] }, "date_published": "2026-09-18T08:00:00+00:00", "date_modified": "2026-09-18T08:00:00+00:00" }, { "id": "NCT06821087:2026-09-17", "url": "https://clinicaltrials.gov/study/NCT06821087", "title": "Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19", "content_text": "Completed · Phase 2 · Ketamine Only — Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called \"brain fog\"). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongoi…", "summary": "Completed · Phase 2 · Ketamine Only — Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called \"brain fog\"). Long COVID is a condition that affects people even after they have ", "tags": [ "All conditions", "Completed", "Ketamine Only" ], "_osmf": { "nct_id": "NCT06821087", "status": "COMPLETED", "phase": "PHASE2", "start_date": "2025-06-05", "last_updated": "2026-09-17", "agents": [ "Ketamine Only" ] }, "date_published": "2026-09-17T08:00:00+00:00", "date_modified": "2026-09-17T08:00:00+00:00" }, { "id": "NCT05618067:2026-09-16", "url": "https://clinicaltrials.gov/study/NCT05618067", "title": "The Impact of Improved Vagal Function on Periaqueductal Gray Connectivity", "content_text": "Not Yet Recruiting · Not applicable · Breathing Exercise Training — This study is being to see if participating in breathing exercise training and practicing this training will help with Postural tachycardia syndrome (POTS). The information may help doctors to learn more about how the different parts of people's brains communicate.", "summary": "Not Yet Recruiting · Not applicable · Breathing Exercise Training — This study is being to see if participating in breathing exercise training and practicing this training will help with Postural tachycardia syndrome (POTS). The information may help doctors to learn more about how the different part", "tags": [ "All conditions", "Not Yet Recruiting", "Breathing Exercise Training" ], "_osmf": { "nct_id": "NCT05618067", "status": "NOT_YET_RECRUITING", "phase": "NA", "start_date": "2028-01", "last_updated": "2026-09-16", "agents": [ "Breathing Exercise Training" ] }, "date_published": "2026-09-16T08:00:00+00:00", "date_modified": "2026-09-16T08:00:00+00:00" }, { "id": "NCT05851859:2026-09-14", "url": "https://clinicaltrials.gov/study/NCT05851859", "title": "Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital", "content_text": "Recruiting · Not applicable · Cardiac Coherence — Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: \" symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persistin…", "summary": "Recruiting · Not applicable · Cardiac Coherence — Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: \" symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respirat", "tags": [ "All conditions", "Recruiting", "Cardiac Coherence" ], "_osmf": { "nct_id": "NCT05851859", "status": "RECRUITING", "phase": "NA", "start_date": "2025-05-05", "last_updated": "2026-09-14", "agents": [ "Cardiac Coherence" ] }, "date_published": "2026-09-14T08:00:00+00:00", "date_modified": "2026-09-14T08:00:00+00:00" }, { "id": "NCT07655375:2026-09-10", "url": "https://clinicaltrials.gov/study/NCT07655375", "title": "Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut", "content_text": "Recruiting · Not applicable · Sample Collection — Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no…", "summary": "Recruiting · Not applicable · Sample Collection — Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (s", "tags": [ "All conditions", "Recruiting", "Sample Collection" ], "_osmf": { "nct_id": "NCT07655375", "status": "RECRUITING", "phase": "NA", "start_date": "2026-08-18", "last_updated": "2026-09-10", "agents": [ "Sample Collection" ] }, "date_published": "2026-09-10T08:00:00+00:00", "date_modified": "2026-09-10T08:00:00+00:00" }, { "id": "NCT06933173:2026-09-09", "url": "https://clinicaltrials.gov/study/NCT06933173", "title": "RCT of Mind-body in Long COVID and Myalgic Encephalomyelitis", "content_text": "Recruiting · Not applicable · Dynamic Neural Retraining System — We are studying the effect of a mind-body treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with or without Long COVID (LC). Our team recognizes that ME/CFS and Long COVID are serious, debilitating, biomedical conditions. ME/CFS can affect many different parts of …", "summary": "Recruiting · Not applicable · Dynamic Neural Retraining System — We are studying the effect of a mind-body treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with or without Long COVID (LC). Our team recognizes that ME/CFS and Long COVID are serious, debilitating, ", "tags": [ "All conditions", "Recruiting", "Dynamic Neural Retraining System" ], "_osmf": { "nct_id": "NCT06933173", "status": "RECRUITING", "phase": "NA", "start_date": "2025-07-10", "last_updated": "2026-09-09", "agents": [ "Dynamic Neural Retraining System" ] }, "date_published": "2026-09-09T08:00:00+00:00", "date_modified": "2026-09-09T08:00:00+00:00" } ] }